New ZS Research Answers Three Key Questions About the Oncology Customer Experience in the EU5

Posted by Richard Secker-Johnson on Apr 19, 2018 8:00:00 AM

Malik Kaman co-wrote this blog post with Richard Secker-Johnson. 

For several years now, ZS has been running a customer experience report with oncologists in the U.S., and each year our clients have asked us to explore the impact and drivers of a positive customer experience in Europe, as well. In an online survey, which we fielded to 333 oncologists and hematologists across the EU5 (France, Germany, Italy, Spain and the U.K.), we asked physicians to rate their experiences with the top 18 oncology drug manufacturers. Our goal was to answer three questions facing all oncology manufacturers today. The results offer key insights into how companies can differentiate in this increasingly competitive landscape.


>
Read More

A New Era of Biosimilars in Oncology: Four Themes From ESMO 2017

Posted by Christina Corridon on Sep 21, 2017 12:30:53 PM

The European healthcare landscape has more than a decade of in-market experience with supportive care biosimilars. However, we’re entering a new era for biosimilars in oncology with the recent launch of therapeutic biosimilars in the EU.

At the recent European Society for Medical Oncology (ESMO) Congress, held Sept. 8-12 in Madrid, the European medical industry came together for clinical data updates, expertise-sharing and advisory guidance. There were six presentations on biosimilars at the event, including those sponsored by biosimilar manufacturers. Consistent across many sessions were four core themes:


>
Read More